Cadonilimab (AK104) is a targeting PD1/CTLA4 IgG1 scaffold Fc-engineered humanized bispecific antibody. Cadonilimab can be used for researching metastatic cervical cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).
Purity:
>99.0%
CAS Number:
[2394841-59-7]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted